<DOC>
	<DOCNO>NCT00170378</DOCNO>
	<brief_summary>To study safety efficacy early administration Low Molecular Weight Heparin patient traumatic brain injury .</brief_summary>
	<brief_title>The Use Low Molecular Weight Heparin Traumatic Brain Injury</brief_title>
	<detailed_description>Venous thromboembolic ( VTE ) prophylaxis trauma patient critical clinical problem . Patients traumatic brain injury usually effective VTE prophylaxis withhold secondary concern exacerbate intracranial hemorrhage . This study examine safety efficacy early administration ( within 24 hrs admission ) low molecular weight heparin patient population high VTE risk .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Blunt traumatic brain injury ( Marshall IIV ) Stable 6 hr . head CT Stable hemoglobin Premorbid coagulopathy Pregnancy &lt; 18 y.o . Need therapeutic anticoagulation Heparin allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Enoxaparin</keyword>
	<keyword>Safety</keyword>
</DOC>